Search
Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions
He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes. Brought to you by
6 hours ago
SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings
He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.
Jan 13
SF Healthcare Week: A buy side perspective of biotech with Affinity's Patrick Nosker
Patrick Nosker gives his take on today's conference news and highlights the science behind some of his firm's top holdings.
Jan 8, 2024
.png){kind=logo}
